Clinical Trial Update: Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial [Phase 3]

View source ↗

Summary

Phase 3 multicenter double-blind randomized trial evaluating rituximab for progressive interstitial lung disease with inflammatory component; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Lung Diseases | Phase 3 | Status: RECRUITING